Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

61P - Prognostic impact in ovarian cancer carriers of mutations located in cluster with higher risk of ovarian cancer in BRCA

Date

20 Jun 2024

Session

Poster Display

Presenters

Pablo Torres-Mozas

Citation

Annals of Oncology (2024) 9 (suppl_5): 1-19. 10.1016/esmoop/esmoop103501

Authors

P. Torres-Mozas, R. Garcia Munoz, F. Galvez Montosa

Author affiliations

  • Hospital Universitario de Jaén, Jaén/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 61P

Background

The information between the phenotype and genotype in ovarian cancer (OC) carrying a BRCA mutation (BRCAmut) has been the subject of some publications in recent years. Rebbeck's work reports a mapping of the BRCA1 and 2 genes in which several areas are found that function as association clusters with a greater risk of suffering from OC. To date, it has not been reported whether the mutations that affect these areas have a prognostic impact on patients affected by BRCAmut CO or on the results of treatment with IPARP.

Methods

283 patients with ovarian cancer treated in our unit between 2011 and 2023 with a mutational study that includes the BRCA genes are reviewed. The clusters with higher risk of ovarian cancer are defined as follows: BRCA1: c.1380-4062aa BRCA2: c.3249-5681aa and c.6645-7471aa.

Results

In the log-rank test, there is a tendency towards significance (p: 0.071) of a worse prognosis of patients carrying mutations in the association cluster with OC. Among the patients who received iPARP, there were no statistically significant differences between both groups (p:0.69), although the number of patients in the group with mutations in the CO cluster was only 3 patients. Table: 61P

Patients' clinical data

Number of patients 49
Median age (years) 55
Histological types (N, %)
High grade serous carcinoma 42 (85,8%)
High grade endometrioid carcinoma 4 (8,2%)
Mucinous carcinoma 1 (2%)
Carcinosarcoma 1 (2%)
Undifferentiated carcinoma 1 (2%)
Stage at diagnosis
I 4 (8,2%)
II 2 (4.1%)
III 29 (59,2%)
IV 14 (28,5%)
BRCAmut
BRCA1 27 (55,2%)
Ovarian cluster 6 (22,2%)
BRCA2 22 (44,8%)
Ovarian cluster 1 (4,5%)
iPARP treatment 33 (67.3%)
Olaparib 28 (84.8%)
Niraparib 5 (15,2%)

Conclusions

A trend towards significance is seen regarding the worse prognosis conferred by the BRCA mutation located in the OC association cluster. Treatment with iPARP seems to compensate for this point, at least partially. A larger number of patients is necessary to validate this hypothesis, for which national registry work launched in various countries, or even collaboration between them, can be a very useful tool.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.